Our success stories

Read the stories from the teams behind some of our most important achievements, from bringing drugs to market to spinning out new companies and developing essential partnerships.

Bispecific antibody coloured heavy chain in green and pink, light chain blue and yellow against grey background; glycosylated bispecific immunoglobulin engineered to target different antigens 3D render

MOv18 – opening a new front for immunotherapy

Hear from Sophia Karagiannis and James Spicer on their journey to get the first IgE anti-cancer drug into humans.

Tumour cells under microscope labelled with fluorescent molecules

A new culture – how CRUK is helping to take organoids global

Learn how cancer patient-derived organoids from Japan’s Fukushima Medical University became the latest tech to be made available via CancerTools.org.

A new approach to cancer immunotherapy

The story of gamma delta T cells from discovery to clinical trials

Taking on DNA repair to tackle cancer

From discovery to translation - the story of pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in cancers.

Speaking a thousand words – how a cancer image collection is set to improve AI diagnosis

The OPTIMAM project’s mammogram collection is heralding a new dawn of machine-learning-based cancer detection.

Photomicrograph of a diffuse large B-cell lymphoma

Coming together for Zynlonta

How scientific expertise, funding and entrepreneurship came together for the development of an antibody-drug conjugate targeting lymphoma

How UK researchers commercialised CD25 as an immunotherapy drug target

Guided by Cancer Research Horizons in collaboration with Roche, Cancer Research UK scientists develop a new antibody that can target CD25.

PARP inhibitors: Halting cancer by halting DNA repair

Read how researchers supported by Cancer Research UK deciphered how blocking DNA repair could expose a weak point in the biology of cancer cells.

Explore more

A group of people in discussion, mingling at a networking event

Interested in progressing world-leading cancer research?

We want to hear from researchers, entrepreneurs, partners and investors.

Contact us